Long-Acting Somatostatin Analogues are Highly Effective in Patients with Early Stage MEN-1-Related Well-Differentiated Neuroendocrine Tumors Abstract #549

Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected with functioning well-differentiated neuroendocrine tumors (NET). There are no studies specifically focusing on NET associated to Multiple Endocrine Neoplasia type 1 (MEN-1).
Aim(s): To evaluate the efficacy of long-acting somatostatin analogues in MEN-1 patients affected with duodeno-pancreatic NET.
Materials and methods: All first-degree relatives of MEN-1 subjects, genetically diagnosed for MEN-1 before the clinical diagnosis of NET and with evidence of one or more duodeno-pancreatic NET <15 mm in size, were enrolled. Twenty-two patients with MEN-1-related duodeno-pancreatic NET (age range 21-42 yrs) were treated with Octreotide LAR (30mg/28 days). Treatment duration ranged 1-7 yrs. At the radiological evaluation (performed by multidetector-row computed tomography and endoscopic ultrasound), multiple duodeno-pancreatic NET (range 1-8), sized 3–14 mm, were detected.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Antongiulio Faggiano

To read results and conclusion, please login ...

Further abstracts you may be interested in

#901 Impact of Long-Acting Octreotide in Patients with Early-Stage MEN1-Related Duodeno-Pancreatic Neuroendocrine Tumors
Introduction: Somatostatin analogues (SSA) represent one of the main therapeutic options in patients affected by functioning well-differentiated neuroendocrine tumors (NETs). There are no studies specifically focusing on NETs associated with Multiple Endocrine Neoplasia type 1 (MEN1).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: MD Valeria Ramundo
#1191 Efficacy of Lanreotide versus Follow-up in Early-stage Duodeno-Pancreatic Neuroendocrine Tumors (NETs) Related to Multiple Endocrine Neoplasia Type 1 (MEN1): Preliminary Data
Introduction: Surgery is the only curative approach for NETs, representing the first-line therapy. As most pts with MEN1 have multiple duodeno-pancreatic NETs, cure is generally not possible, unless to adopt radical surgery. Somatostatin analogues (SSAs) represent one of the main therapeutic option in functioning well-differentiated NETs. There are no perspective studies focusing on MEN1-related NETs.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: DR. Valeria Ramundo
#2695 Different Treatment Options for Patients with Advanced Gastrointestinal Neuroendocrine Tumors
Introduction: Low sensitivity to chemotherapy leaves open question of optimal approach to drug therapy of neuroendocrine tumors (NETs). Somatostatin analogues (SSA) (octreotide, lanreotide) and mTOR inhibitors are successfully used in treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Alina Isiangulova
Authors: Isiangulova A, Khasanov R, ...
#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors
Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Anna Kuznetsova
#2888 Progression-Free Survival as a Surrogate Endpoint in Gastroenteropancreatic Neuroendocrine Tumors Treated with Somatostatin Analogues
Introduction: Progression-free survival (PFS) has been used as surrogate endpoint in phase III trials with somatostatin analogues for gastroentero-pancreatic neuroendocrine tumors (GEP-NET). However, this endpoint has not been validated in this scenario.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: Alberto Carmona-Bayonas